Gene therapy applications in gynecologic malignances management;Terapia genowa i jej zastosowanie w leczeniu nowotworów ginekologicznych

Ginekologia Polska

Volumn 81, Issue 1, 2010, Pages 50-54

  Agnieszka, Gromadzka ^b   Marta, Kubiczak ^b   Anna, Jankowska ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Autorki w równym stopniu uczestniczyły w przygotowaniu artykułu ^*  (Poland)

Author keywords

Antiangiogenic agents; Gene therapy; Immunotherapy; Proapoptotic therapy; SiRNA; Transgenic suicide gene

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

APOPTOSIS; DOSE RESPONSE; DRUG EFFECT; FEMALE; FEMALE GENITAL TRACT TUMOR; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNOTHERAPY; METHODOLOGY; REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE TARGETING; GENE THERAPY; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOTHERAPY;

EID: 77950570665     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Szala S. Terapia genowa. Warszawa: Wydawnictwo Naukowe PWN, 2003.
2. Fire A, Xu S, Montgomery M, [et al.]. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998, 391, 806-811.
3. Vasudevan S, Steitz J. AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. Cell. 2007, 128, 1105-1118.
4. Zhang L, Yang N, Mohamed-Hadley A, [et al.]. Vector-based RNAi: a novel tool for isoformspecific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun. 2003, 303, 1169-1178.
5. Wilczyński J, Kufelnicka M, Smolarz B, [et al.]. Czy gen MDR 1 jest kluczem do efektywnej chemoterapii. Ginekol Pol. 2006, 77, 476-484.
6. Wu H, Hait W, Yang J-M. Small interfering RNA-induced suppression of mdr1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003, 63, 1515-1519.
7. Hua J, Mutch D, Herzog T. Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. Gynecol Oncol. 2005, 98, 31-38.
8. Numnum T, Makhija S, Lu B, [et al.]. Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Gynecol Oncol. 2008, 108, 34-41.
9. Bergers G, Benjamin L. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003, 3, 401-410.
10. Boocock C, Charnock-Jones D, Sharkey A, [et al.]. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst. 1995, 87, 506-16.
11. Paley P, Staskus K, Gebhard K, [et al.]. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer. 1997, 80, 98-106.
12. Loncaster J, Cooper R, Logue J, [et al.]. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer. 2000, 83, 620-625.
13. Olson T, Mohanraj D, Carson L, [et al.]. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 1994, 54, 276-280.
14. Santin A, Hermonat P, Ravaggi A, [et al.]. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol. 1999, 20, 177-181.
15. Mahasreshti P, Navarro J, Kataram M, [et al.]. Adenovirus-mediated Soluble FLT-1 Gene Therapy for Ovarian Carcinoma. Clin Cancer Res. 2001, 7, 2057-2066.
16. Perletti G, Concardi P, Giardini R, [et al.]. Antitumor activity of endostatin against carcinogeninduced rat primary mammary tumors. Cancer Res. 2000, 60, 1793-1796.
17. Subramanian I, Ghebre R, Ramakrishnan S. Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Ther. 2005, 12, 30-38.
18. Niculescu-Duvaz I, Springer C. Introduction to the background, principles and state of the art in suicide gene therapy. Mol Biotechnol. 2005, 30, 71-88.
19. Kunshige I, Samejima Y, Shiki Y, [et al.]. Suicide gene therapy for human uterine adenocarcinoma cells using herpes simplex virus thymidine kinase. Gynecol Oncol. 1999, 72, 16-25.
20. Kammertoens T, Gelbmann W, Karle P, [et al.]. Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine. Cancer Gene Ther. 2000, 7, 629-636.
21. Hamel W, Magnelli L, Chiarugi V, [et al.]. Herpes simplex virus thymdine kinase/ganciclovirmediated apoptotic death of bystander cells. Cancer Res. 1996, 56, 2697-2702.
22. Fillat C, Carrio M, Cascante A, [et al.]. Suicide gene therapy mediated by herpes simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr Gene Ther. 2003, 3, 13-26.
23. El-Aneed A. Current strategies in cancer gene therapy. Eur J Pharmacol. 2004, 498, 1-8.
24. Freeman S, Abbound C, Whartenby K, [et al.]. The " bystander effect" : tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993, 53, 5274-5283.
25. Disis M, Bernhard H, Jaffee E. Use of tumor-responsive T cells as cancer treatment. Lancet. 2009, 373, 673-83.
26. Rosenberg S, Restifo N, Yang J, [et al.]. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008, 8, 299-308.
27. Gao J, Okada N, Mayumi T, [et al.]. Immune cell recruitment and cell-based system for cancer therapy. Pharm Res. 2008, 25,752-68.
28. Stoff-Khalili M, Dall P, Curiel D. Gene therapy for carcinoma of the breast. Cancer Gene Ther. 2006, 13, 633-647.
29. Purabi R, Madhur G, Kamlesh K. Biological Response Modifiers in Cancer. Med Gen Med, 2006, 8, 33.
30. Dutcher J, Wadler S, Wiernik P. Biologic response modifiers in gynecologic malignancies. Yale J Biol Med. 1988 61, 367-378.
31. Chang C, -Tsai T, He L, [et al.]. Cancer Immunotherapy Using Irradiated Tumor Cells Secreting Heat Shock Protein 70. Cancer Res. 2007, 67, 10047-1057.
32. Argento M, Hoffman P, Gauchez A. Ovarian cancer detection and treatment: current situation and future prospects. Anticancer Res. 2008, 28, 3135-3138.
33. Rosenberg S, Restifo N, Yang J, [et al.]. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008, 8, 299-308.
34. Yoon S, Lee J, Cho H, [et al.]. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther. 2009, 16, 489-497.
35. Kershaw M, Westwood J, Parker L, [et al.], A phase - study on adoptive immunotherapy using gene-modified T cells for ovarian cancer, Clin Cancer Res. 2006, 12, 6106-6115..
36. Elmore S. Apoptosis: A Review of Programmed Cell Death. Toxicol Pathol. 2007, 35, 495-516.
37. Askhenazi A, Herbst R. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest. 2008, 118, 1979-1990.
38. Tabuchi Y, Matsuoka J, Gunduz M, [et al.]. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol. 2009, 34, 313-319.
39. Butler S, Iles R. Ectopic human chorionic gonadotropin beta secretion by epithelial tumors and human chorionic gonadotropin beta-induced apoptosis in Kaposi's sarcoma: is there a connection? Clin Cancer Res. 2003, 9, 4666-4673.
40. Nowak-Markwitz E, Jankowska A, Spaczyński M. Gonadotropiny a rak jajnika. Ginekol Pol. 2005, 76, 153-162.
41. Jankowska A, Gunderson S, Andrusiewicz M, [et al.]. Reduction of human chorionic gonadotropin beta subunit expression by modified U1 snRNA caused apoptosis in cervical cancer cells. Mol Cancer. 2008, 7:26.
42. Lleonart M, Artero-Castro A, Kondoh H. Senescence induction; a possible cancer therapy. Mol Cancer. 2009, 8, 3.